Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
MacGregor Cox, Thomas P. Peacock, William T. Harvey, et al.
Nature Reviews Microbiology (2022) Vol. 21, Iss. 2, pp. 112-124
Open Access | Times Cited: 267

Showing 1-25 of 267 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 411
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting
Ayijiang Yisimayi, Weiliang Song, Jing Wang, et al.
Nature (2023) Vol. 625, Iss. 7993, pp. 148-156
Open Access | Times Cited: 149
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Pan-Pan Zhou, Ge Song, Hejun Liu, et al.
Immunity (2023) Vol. 56, Iss. 3, pp. 669-686.e7
Open Access | Times Cited: 118
SARS-CoV-2 evolution in the Omicron era
Cornelius Roemer, Daniel J. Sheward, Ryan Hisner, et al.
Nature Microbiology (2023) Vol. 8, Iss. 11, pp. 1952-1959
Closed Access | Times Cited: 77
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 944-944
Open Access | Times Cited: 70
Prevalence of persistent SARS-CoV-2 in a large community surveillance study
Mahan Ghafari, Matthew Hall, Tanya Golubchik, et al.
Nature (2024) Vol. 626, Iss. 8001, pp. 1094-1101
Open Access | Times Cited: 66
Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
Andrew Evans, Cathy Qi, Jubril Omololu Adebayo, et al.
Journal of Infection (2023) Vol. 86, Iss. 4, pp. 352-360
Open Access | Times Cited: 44
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting
Ayijiang Yisimayi, Weiliang Song, Jing Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 43
Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
Xiaoxin Chen, Xiaodong Huang, Qinhai Ma, et al.
Nature Microbiology (2024) Vol. 9, Iss. 4, pp. 1075-1088
Open Access | Times Cited: 31
Real-time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance
Marc Struelens, Catherine Ludden, Guido Werner, et al.
Frontiers in Science (2024) Vol. 2
Open Access | Times Cited: 24
Evolution of the SARS-CoV-2 Omicron Variants: Genetic Impact on Viral Fitness
Wenhao Liu, Zehong Huang, Jin Xiao, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 184-184
Open Access | Times Cited: 23
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13550-13571
Open Access | Times Cited: 23
Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies
Daniel J. Sheward, Pradeepa Pushparaj, Hrishikesh Das, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 6, pp. 101577-101577
Open Access | Times Cited: 22
Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion
Song Xue, Yuru Han, Fan Wu, et al.
Protein & Cell (2024) Vol. 15, Iss. 6, pp. 403-418
Open Access | Times Cited: 21
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Implications of diversity in sperm size and function for sperm competition and fertility
Montserrat Gomendio, Eduardo R. S. Roldán
The International Journal of Developmental Biology (2008) Vol. 52, Iss. 5-6, pp. 439-447
Open Access | Times Cited: 182
Systematic review and meta‐analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID ‐19 in immunocompromised patients
Rhea Suribhatla, Thomas Starkey, Maria C. Ionescu, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 5, pp. 813-823
Open Access | Times Cited: 33
Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19
Kevin E. Kip, Erin K McCreary, Kevin Collins, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 4, pp. 496-504
Open Access | Times Cited: 31
Broad-spectrum pan-genus and pan-family virus vaccines
Chee Wah Tan, Sophie Valkenburg, Leo L. M. Poon, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 6, pp. 902-916
Open Access | Times Cited: 23
Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies
Niloofar Faraji, Tahereh Zeinali, Farahnaz Joukar, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e30208-e30208
Open Access | Times Cited: 13
Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains
L L Chen, Mengmeng Sun, Huajun Zhang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19
Jenny Andrea Arévalo-Romero, Sandra M. Chingaté-López, Bernardo Camacho, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26423-e26423
Open Access | Times Cited: 9
Single-Molecule Investigation of the Binding Interface Stability of SARS-CoV-2 Variants with ACE2
Ankita Ray, Tran Thi Minh Thu, Rita dos Santos Natividade, et al.
ACS Nanoscience Au (2024) Vol. 4, Iss. 2, pp. 136-145
Open Access | Times Cited: 8
A generalized framework to identify SARS-CoV-2 broadly neutralizing antibodies
Fanchong Jian, Anna Z. Wec, Leilei Feng, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 8
Cross-reactive sarbecovirus antibodies induced by mosaic RBD-nanoparticles
Chengcheng Fan, Jennifer R. Keeffe, Kathryn E. Malecek, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top